Ticker	Volume	Price	Price Delta
DJIA	15,179.80	+109.67	0.73%
S&P 500	1,639.04	+12.31	0.76%
Nasdaq	3,452.13	+28.58	0.83%

Ticker

Volume

Price

Price Delta

DJIA

15,179.80

+109.67

0.73%

S&P 500

1,639.04

+12.31

0.76%

Nasdaq

3,452.13

+28.58

0.83%

Ticker	Volume	Price	Price Delta
STOXX 50	2,687.79	-14.90	-0.55%
FTSE 100	6,322.49	-8.00	-0.13%
DAX	8,180.97	-34.76	-0.42%

Ticker

Volume

Price

Price Delta

STOXX 50

2,687.79

-14.90

-0.55%

FTSE 100

6,322.49

-8.00

-0.13%

DAX

8,180.97

-34.76

-0.42%

Ticker	Volume	Price	Price Delta
Nikkei	13,007.30	-25.84	-0.20%
Hang Seng	21,141.70	-84.17	-0.40%
S&P/ASX 200	4,814.35	-11.53	-0.24%

Ticker

Volume

Price

Price Delta

Nikkei

13,007.30

-25.84

-0.20%

Hang Seng

21,141.70

-84.17

-0.40%

S&P/ASX 200

4,814.35

-11.53

-0.24%

Glaxo Bid Undervalues Human Genome Sciences, Sunday Times Says

By Lucy Meakin - 2012-04-29T10:34:05Z

GlaxoSmithKline Plc (GSK)’s $2.6 billion offer for Human Genome Sciences Inc. (HGSI) “completely undervalues” the company according to a major shareholder, the Sunday Times reported.

Mark Evans from Taube Hodson Stonex Partners LLP, a fund manager that owns 5.6 percent of the U.S. drugs maker, termed the bid “unacceptable,” the London-based newspaper said.

Human Genome rejected Glaxo’s $13-a-share cash offer on April 19.

To contact the reporter on this story: Lucy Meakin in London at lmeakin1@bloomberg.net

To contact the editor responsible for this story: Daniel Tilles at dtilles@bloomberg.net

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.